on a single project could jeopardize continued funding on any or 
all recombinant DNA work at the institution. 
Dr. McKinney said he believed this could be interpreted also to 
cover a third party action in which an institution funded by NIH 
could be held responsible for research initiated by them and 
turned over to a second party who, in turn, allow a third party 
to continue further research without the consent or knowledge of 
the originating institution. 
Dr. Atlas said he would prefer the phrase "or done in 
collaboration with," to be put in the language of the proposal to 
obviate the innocent third party liability. 
Mr. Brewer said he would accept "in collaboration with" as an 
additional phrase. 
Dr. McGarrity asked whether he could get a feeling of the 
committee as to which proposal they were more comfortable with. 
Dr. Riley asked Dr. Gottesman what was in her proposed language 
that was not in the Brewer proposal. She replied the major 
difference was the reiteration of the "direct extension" 
terminology. She said she was not sure that "collaboration" 
would fit in the proposed language but said the phrase "sponsored 
by" could be footnoted to include "collaboration." 
Dr. Cohen said the concept of "collaboration" would eliminate the 
"direct extension" phraseology because it involves active 
participation and he said it dealt with the problem nicely. 
Mr. Brewer then reiterated his proposal in the form of a motion 
to read: 
"The Guidelines are applicable to all recombinant DNA 
research conducted at or sponsored by or done in 
collaboration with an institution that receives any 
support for recombinant DNA research from the National 
Institutes of Health (NIH) . This includes research 
performed by NIH directly. 
"An individual receiving support for research involving 
recombinant DNA must be associated with or sponsored by 
an institution that can and does assume the 
responsibilities assigned in these Guidelines. 
"For any recombinant DNA research done in another 
country, if that country has established rules for the 
conduct of recombinant DNA projects, then a certificate 
of compliance with those rules may be submitted to the 
NIH as evidence of compliance with the NIH Guidelines. 
Alternatively, if the host country does not have such 
rules, written acceptance of the proposed project by an 
1152 ] 
Recombinant DNA Research, Volume 13 
